Open an account

Autonomix Medical

AMIX · NASDAQ

$2.61−$0.04 (−1.51%)TodayMarket closed ·
Prev close $2.65

About AMIX

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. The company is headquartered in The Woodlands, Texas and currently employs 8 full-time employees. The company went IPO on 2024-01-29. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. The company is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The firm is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.

Employees
8
Headquarters
The Woodlands, Texas
Listed
Jan 29, 2024
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
autonomix.com

AMIX key statistics

Market cap
5.12M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
214.15K
Volume
27.51K
Open price
$2.69
High today
$2.69
Low today
$2.60
52 Week high
$32.55
52 Week low
$2.44

Autonomix Medical (AMIX) at a glance

Autonomix Medical (AMIX) last traded at $2.61, with a market cap of 5.12M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.60 and $2.69. The current price is 0.4% above the day's low and 3.0% below its high.

Volume so far is 27.51K shares, below the average of 214.15K shares a day.

Over the past year Autonomix Medical has ranged from $2.44 to $32.55, and now sits 1% of the way up that range.

Autonomix Medical met or beat analyst EPS estimates in 4 of the last 6 quarters. In Q1 FY27 it reported -$5.02 per share against an estimate of -$6.53.

The average analyst price target is $59.98, 2197.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $59.98
Low
$42.42
Now
$2.61
High
$79.38

AMIX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 6 quarters, by 25.0% on average.

  1. Q2 FY25: reported -$51.87 per share against an estimate of $0.00
  2. Q3 FY25: reported -$30.66 per share against an estimate of -$51.41
  3. Q4 FY25: reported -$38.01 per share against an estimate of -$26.45
  4. Q1 FY26: reported -$4.83 per share against an estimate of -$5.57
  5. Q2 FY26: reported -$5.02 per share against an estimate of -$6.53
  6. Q1 FY27: reported -$5.02 per share against an estimate of -$6.53

AMIX news

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Market-Moving News for August 25th

  • Tanya Rawat

    Autonomix Medical (AMIX) Stock Surges 117% After Hours: Here’s Why

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Shivdeep Dhaliwal

    SpaceX, AMD, Nvidia, Astera Labs and Autonomix Medical: Why These 5 Stocks Are on Investors' Radars Today

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

Similar companies

Companies in the same industry as Autonomix Medical

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.